Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Conroy T, Ychou M, Bouché O, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1842.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• ESMO Guidelines Committee. Cancer of the pancreas: ESMO clinical practice guidelines. eUpdate; 2019. Available from: https://www.esmo.org/guidelines/gastrointestinal-cancers/pancreatic-cancer.
   Google Scholar
• Nationale kliniske retningslinjer. Dansk Pancreas Cancer Gruppe; 2020. Avaiable from: http://dpcg.gicancer.dkdefault?pID=22.
   Google Scholar
• Klompmaker S, van Hilst J, Gerritsen SL, E-AHPBA DP-CAR Study Group, et al. Outcomes after distal pancreatectomy with celiac axis resection for pancreatic cancer: a Pan-European retrospective cohort study. Ann Surg Oncol. 2018;25(5):1440–1447.
   PubMed Web of Science ®Google Scholar
• Taylor LJ, Greenberg CC, Lidor AO, et al. Utilization of surgical treatment for local and locoregional esophageal cancer: Analysis of the national cancer data base. Cancer. 2017;123(3):410–419.
   PubMed Web of Science ®Google Scholar
• Merritt RE, Abdel-Rasoul M, Fitzgerald M, et al. The academic facility is associated with higher utilization of esophagectomy and improved overall survival for esophageal carcinoma. J Gastrointest Surg. 2021;25(7):1677–1689.
   PubMed Web of Science ®Google Scholar
• Hauser A, Dutta SW, Showalter TN, et al. Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. J. Clin. Neurosci. 2018;47:103–110.
   PubMed Web of Science ®Google Scholar
• Chu QD, Zhou M, Peddi P, et al. Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma. HPB. 2017;19(12):1046–1057.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Mau L-W, Chitphakdithai P, et al. Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplant. 2020;55(5):906–917.
   PubMed Web of Science ®Google Scholar
• Go RS, Al-Hamadani M, Shah ND, et al. Influence of the treatment facility volume on the survival of patients with non-Hodgkin lymphoma. Cancer. 2016;122(16):2552–2559.
   PubMed Web of Science ®Google Scholar
• Master S, Munker R, Shi Z, et al. Insurance status and other non-biological factors predict outcomes in acute myelogenous leukemia: analysis of data from the national cancer database. Anticancer Res. 2016;36(9):4915–4921.
   PubMed Web of Science ®Google Scholar
• Go RS, Bartley AC, Crowson CS, et al. 3rd. Association between treatment facility volume and mortality of patients with multiple myeloma. J Clin Oncol. 2017;35(6):598–604.
   PubMed Web of Science ®Google Scholar
• Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(24):2545–2556.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Cuhna AS, Caramella C, ESMO Guidelines Committee, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–68.
   PubMed Web of Science ®Google Scholar
• Kirkegård J, Aahlin EK, Al-Saiddi M, et al. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Br J Surg. 2019;106(6):756–764.
   PubMed Web of Science ®Google Scholar
• Tamburini N, Maniscalco P, Mazzara S, et al. Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study. Eur J Cardiothorac Surg. 2018;53(6):1199–1204.
   PubMed Web of Science ®Google Scholar
• Pakkeforløb for kraeft i bugspytkirtlen. Danish Health Authority 1–32; 2016. Avaiable from: https://www.sst.dk/da/sygdom-og-behandling/kraeft/pakkeforloeb//-/media/Udgivelser/2019/Pakkeforloeb-kraeft-2015-2019/Bugspytkirtlen-2016/Pakkeforløb-for-kraeft-i-bugspytkirtlen-–-revision-sep-2016_endelig.ashx.
   Google Scholar
• Rasmussen LS, Fristrup CW, Jensen BV, et al. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: a nationwide unselected real-world register study. Eur J Cancer. 2020;129:50–59.
   PubMed Web of Science ®Google Scholar
• Fristrup C, Detlefsen S, Hansen CP, et al. Danish pancreatic cancer database. Clin Epidemiol. 2016;8:646–648.
   Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The danish national patient registry: a review of content, data quality, and research potential. CLEP. 2015;7:449–490.
   Web of Science ®Google Scholar
• Dansk Pancreas Cancer Database. Sundhed.dk; 2020. Avaiable from: https://www.sundhed.dk/sundhedsfaglig/kvalitet/kliniske-kvalitetsdatabaser/kraeft/kraeft-i-bugspytkirtlen/.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Kraemer PC, Schmidt HH, Ladekarl M. Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer. Dan Med J. 2014;61(4):A4819.
   PubMed Web of Science ®Google Scholar
• Canale TD, Cho H, Cheung WY. A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes. Med Oncol. 2018;35:116.
   PubMed Web of Science ®Google Scholar
• Kirkegård J, Ladekarl M, Fristrup CW, et al. Urban versus rural residency and pancreatic cancer survival: a Danish nationwide population-based cohort study. PLoS One. 2018;13(8):e0202486.
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Ladekarl M, Mortensen MB, et al. Chemotherapy for patients with non-resectable pancreatic cancer with additional chemo-radiotherapy for patients with potentially resectable tumours: Final results. J Clin Oncol. 2016;34(15_suppl):e15725–e15725.
   Web of Science ®Google Scholar
• Sharma MB, Carus A, Sunde L, et al. BRCA-associated pancreatico-biliary neoplasms: four cases illustrating the emerging clinical impact of genotyping. Acta Oncol. 2016;55(3):377–381.
   PubMed Web of Science ®Google Scholar
• Caparello C, Vivaldi C, Fornaro L, et al. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Future Oncol. 2016;12(7):901–908.
   PubMed Web of Science ®Google Scholar
• Zhu P, Du XL, Zhu J-J, et al. Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the national cancer database. J. Neurosurg. 2020;132(2):491–502.
   Web of Science ®Google Scholar
• Cai J, Chen H, Lu M, et al. Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis. Cancer Lett. 2021;520:1–11.
   PubMed Web of Science ®Google Scholar
• Noel M, Fiscella K. Disparities in pancreatic cancer treatment and outcomes. Health Equity. 2019;3(1):532–540.
   PubMedGoogle Scholar
• Zhu F, Wang H, Ashamalla H. Racial and socioeconomic disparities in the treatments and outcomes of pancreatic cancer among different treatment facility types. Pancreas. 2020;49(10):1355–1363.
   PubMed Web of Science ®Google Scholar
• Powers BD, Fulp W, Dhahri A, et al. The impact of socioeconomic deprivation on clinical outcomes for pancreatic adenocarcinoma at a high-volume cancer center. Ann Surg. 274(6):e564–e573.
   PubMed Web of Science ®Google Scholar
• Engberg H, Steding-Jessen M, Øster I, et al. Regional and socio-economic variation in survival after a pancreatic cancer diagnosis in Denmark. Dan Med J. 2020;67:A08190438.
   PubMed Web of Science ®Google Scholar
• Shapiro M, Chen Q, Huang Q, et al. Associations of socioeconomic variables with resection, stage, and survival in patients with Early-Stage pancreatic cancer. JAMA Surg. 2016;151(4):338–345.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349.
   Google Scholar